MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527191230/en/
'Brandi joins MindMed at a pivotal moment for the company, bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise,' said Rob Barrow, Chief Executive Officer of MindMed. 'Her proven track record leading public companies through transformative milestones, including initial public offerings (IPO), business development and investor engagement makes her a valuable addition to our organization. As we accelerate toward the potential commercialization of MM120 ODT, her understanding of the healthcare landscape and executional strength will be instrumental in advancing our strategy, driving growth, and delivering long-term value for both patients and shareholders.'
'MindMed is leading a true paradigm shift in mental health treatment, and I'm excited to collaborate with a team renowned for its exceptional depth and breadth of experience in drug development,' said Ms. Roberts. 'With MM120 ODT, the company is advancing a potential breakthrough for the millions of people in the U.S. suffering from GAD and MDD. Joining MindMed is an extraordinary opportunity to continue building a robust financial infrastructure that matches the strength of the Company's science; delivering a comprehensive strategic financial vision built to support innovation, agility, and access with the goal of helping patients and making a meaningful impact in addressing the mental health crisis.'
Ms. Roberts has more than 25 years of financial leadership experience within the life sciences industry. Most recently, she served as CFO and Executive Vice President of Longboard Pharmaceuticals, where she helped lead the company through its IPO, multiple financings, and ultimately, its $2.6 billion acquisition by Lundbeck in 2024. Throughout her career, Ms. Roberts has played pivotal roles in scaling operations, supporting clinical development, and managing investor relations with leading investors, funds, and analysts. She has held CFO roles at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, and senior finance positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts received her MBA from the University of San Diego and her B.S. degree in business administration in Accounting and Finance from the University of Arizona. She is a Certified Public Accountant in the State of California and currently serves on the board of advisors for Life Science Cares San Diego and the board for the Association of Bioscience Financial Officers Southwest chapter.
Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
In connection with her appointment as Chief Financial Officer on June 2, 2025, MindMed will grant Ms. Roberts on such date inducement awards consisting of (i) an option to purchase 500,000 common shares of the Company (the "Option") and (ii) 125,000 performance share units (the 'PSUs') (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting. The Option will have an exercise price equal to the closing price of MindMed's common shares on May 30, 2025, the last trading day on which MindMed's common shares will trade prior to the date of the grant and will vest over a four-year period with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the three-year period thereafter, subject to her continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period.
The inducement awards to Ms. Roberts will be granted as a material inducement to her entering into employment with MindMed and were approved by MindMed's Compensation Committee on May 21, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The awards were granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
Forward-Looking Statements
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's beliefs regarding potential benefits of MM120 ODT for GAD and MDD; the size of the addressable market for MM120 ODT for treatment of GAD and MDD; the Company's plans to appoint Ms. Roberts as CFO effective June 2, 2025, and to grant her inducements awards in connection therewith. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Silver's Options Sizzle: Are Traders Betting on a Breakout?
A notable wave of trading activity swept through several silver-linked assets in early June. Investors saw a significant jump in call option volumes for multiple silver-related equities. Call options give the holder the right, not the requirement, to buy an asset, such as a stock or ETF share, at a pre-set price by a specific date. When call volume spikes, it often signals that some traders believe the asset's price is poised to rise. This unusual call option volume and increased investor interest in multiple stocks and ETFs at the same time warrant a closer look to see what's stirring in the silver sector. Unpacking the Action: A Look at Specific Silver Plays The heightened call option volume in early June varied across multiple silver-related securities, each telling a slightly different story. Separately, they tell four stories of bullish catalysts and heightened investor sentiment, but when combined, they start to reveal the bigger picture of a sector accumulating interest and investment. iShares Silver Trust: A Price Play on Silver Bullion? [content-module:CompanyOverview|NYSE:AG] The iShares Silver Trust (NYSEARCA: SLV), an ETF that aims to track the price of silver bullion, saw 599,279 call option contracts traded. This volume was 57.8% above its usual average. The high call volume may suggest that some traders expect silver prices to rebound soon or are preparing for further price fluctuations. Because SLV tracks physical silver, this option's activity directly reflects views on the metal itself, likely influenced by broader economic news or general market coverage. First Majestic: Mining News Ignites Options Interest? [content-module:CompanyOverview|NYSE:AG] First Majestic Silver Corp. (NYSE: AG), a company focused mainly on silver production, experienced a call option volume of 39,607 contracts, an 80.9% increase from its average. First Majestic's stock price has also climbed around 18% to $7.28 during the first week of June, with a high trading volume. This mix of soaring call options, a rising stock price, and heavy trading often points to strong positive sentiment. Recent good news from the company has also likely played a role. For instance, on May 28, 2025, First Majestic announced a significant gold-silver discovery at its Santa Elena property. This, along with strong financial results from the first quarter of 2025, could lead traders to expect more gains from the stock. Pan American Silver: Big Deal Draws Options Traders? [content-module:CompanyOverview|NYSEARCA:SILJ] Pan American Silver Corp. (NYSE: PAAS), a large, diversified silver producer, recorded 9,098 call option contracts traded, up 25.7% from its average. The company's stock price also rose, gaining nearly 10% in early June. This increased call activity, alongside positive news indicators, suggests investors are reacting well to recent company moves. A key factor is likely Pan American's May 11, 2025, announcement of a deal to acquire MAG Silver Corp. for $2.1 billion. This strategic acquisition is expected to significantly boost Pan American's silver output and potential future earnings, which could, in turn, lift its stock price and attract optimistic options bets. Junior Miners: High Hopes for Smaller Players? [content-module:CompanyOverview|NYSEARCA:SILJ] The Amplify Junior Silver Miners ETF (NYSEARCA: SILJ), which holds smaller silver mining and exploration companies, saw its call option volume hit 14,925 contracts. This was a striking 97.7% leap above its average, and it was also the most significant percentage increase among these assets. SILJ's price also increased by around 10% in early June. This dramatic percentage jump in calls for SILJ points to strong speculative interest in this part of the silver market. Junior miners often have stock prices that move more sharply with silver prices. The high option activity here suggests that some traders may be betting on substantial returns from these smaller firms if silver prices continue to climb or if positive news persists for the sector. Beyond Options: What This Means for the Silver Market When call option volume rises sharply across different types of silver assets, it can signal a broader increase in investor focus on the entire silver sector. Some traders may be positioning for potential price gains. Silver's appeal comes from several areas. Demand from industries utilizing silver in green technologies, such as solar panels, electronics and the automotive sector, remains strong. Silver is also a well-known precious metal. It is often regarded as a valuable investment that retains its value, especially during economic uncertainty or rising inflation. These core factors continue to support interest in the metal. What Spiking Call Volumes Say About Silver's Next Move The notable surge in call option activity across our four assets in early June clearly shows heightened investor focus on the silver sector. This flurry of bullish bets, reflected in the increased demand for call options, suggests that a market segment is positioning for potential upward price movements in silver bullion and mining equities. Whether driven by specific company news or broader shifts in sentiment towards precious metals, the data points to a renewed speculative interest. The significant percentage increase in call volume underscores a willingness among some traders to embrace higher-risk, potentially higher-reward scenarios within the silver space. Ultimately, this concentrated options activity serves as a strong indicator that silver and its related securities captured significant market attention. At the same time, the direct motivations behind each trade can vary, the collective signal points towards a period of dynamic interest and re-evaluation for the silver complex. How these expectations play out will depend on ongoing market fundamentals, company performance, and the broader economic landscape, ensuring that the silver narrative will remain one to watch. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
Globe and Mail
2 hours ago
- Globe and Mail
Why Dollar General Stock Zoomed Nearly 17% Higher This Week
According to data compiled by S&P Global Market Intelligence, discount retailer Dollar General 's (NYSE: DG) share price ballooned by almost 17% across the trading week. In retrospect that wasn't surprising, as the company simply crushed it in its latest earnings report, and analysts fell over themselves publishing bullish new takes on its stock. The dollars rolled in Dollar General delivered its first-quarter figures Tuesday morning, and investors couldn't wait to pile into its shares. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » This was understandable, because those fundamentals were solid. The retailer's net sales climbed more than 5% higher year over year to land at $10.4 billion. This was on the back of a 2%-plus rise in same-store sales, always a core performance metric in the retail industry. Profitability headed north too, with GAAP net income rising almost 8% to slightly under $392 million. In per-share terms, Dollar General earned $1.78. Both headline figures topped the consensus analyst estimates. On average, pundits tracking the stock were modeling $10.25 billion on the top line, and only $1.46 per share for net income. Some of those pundits might not be underestimating Dollar General quite so much. A clutch of them raised their price targets on the stock, with a few even upgrading their recommendations. One of the upgrades was enacted by Oppenheimer 's Rupesh Parikh, who now feels the company is worthy of an overperform (buy) rating at $130 per share, where previously it was only rated a perform (hold). Solid and sustainable According to reports, Parikh was not only impressed by Dollar General's ability to sustain 2% to 3% comparable sales growth figures, he feels it's an excellent play in a recessionary environment. That's been a persistent fear lately of numerous economists and more than a few investors, given the current shakiness in the global and domestic economies. Dollar General definitely seems as if it's on a roll, and it might just become a hot, go-to retailer if those gloomy predictions come true. It's absolutely a stock to consider for our times. Should you invest $1,000 in Dollar General right now? Before you buy stock in Dollar General, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dollar General wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor 's total average return is997% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
3 hours ago
- Globe and Mail
B.C. launches $5-million ad campaign to recruit American doctors, nurses
British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States, citing 'chaos' under the Trump administration to lure them north. The Ministry of Health said the campaign launched on Monday was being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Josie Osborne said at a news conference it was a step B.C. needed to 'take right now' to attract physicians, nurses and other health care workers, and the province would do everything in its power to ease their transition. 'This will help supercharge our overall recruitment campaign to attract U.S. health care workers to B.C.,' she said. Opinion: How to win a trade war Fentanyl czar focused on combatting opioid trade, despite tariff distraction In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'more news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to 'follow your heart' to the province. Osborne said the campaign was expected to reach about 250,000 health care workers. She said B.C. was 'taking advantage of the uncertainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who shared the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Looming over these efforts is the question of whether B.C.'s public single-payer system offers sufficient financial incentives. Osborne said it was difficult to directly compare physician salaries in B.C. with those in the United States. 'But I can say that with some of the recent changes we've made, and how we pay family doctors, we know that we have competitive salaries,' she said. 'We also know that we offer very competitive salaries for nursing. We offer some of the highest nursing wages in Canada. We also know, though, that doctors are not just motivated by dollars and cents.' Osborne said nearly 1,600 health care providers had already expressed an interest in moving to B.C. even before the ads launched. These included 700 doctors and 500 nurses, but she could not say how many had made it to B.C. 'We're going to do everything we can to attract as many physicians and nurses as possible,' she said without giving a specific target number. 'Ultimately, the success is measured by what people experience in their communities,' she added. She said B.C. would eventually expand international recruitment to other jurisdictions, likening the process to hitting a target. 'We've got the U.S. right in the centre, the bull's eye, and then right outside in the next rings, are countries like the United Kingdom,' she said. 'That's where we'll be focusing our efforts next.'
